Uncertainty of Treatment of Serratia marcescens Endocarditis

International Journal of Medical and Pharmaceutical Case Reports

View Publication Info
 
 
Field Value
 
Title Uncertainty of Treatment of Serratia marcescens Endocarditis
 
Creator Goodberlet, Melanie
Schontz, Michael
McLaughlin, Kevin
Kelly, Julie
 
Description Aim: To discuss two patient cases of Serratia marcescens endocarditis and the paucity of literature regarding treatment options.
Presentation of Case: Patient 1 was a 29-year old male who presented with native mitral valve Serratia marcescens endocarditis presumed secondary to intravenous drug use. He was empirically treated with vancomycin and piperacillin/tazobactam then transitioned to meropenem and gentamicin 1 mg/kg every 8 hours. He was maintained on vancomycin monotherapy for days 4-14. Gentamicin was restarted on hospital day 14 at 7 mg/kg every 36 hours for 6 weeks. He underwent mitral valve replacement on hospital day 20. He was readmitted on day 42 with splenic lesions and enlarging mycotic aneurysms. Patient 2 was a 38-year old male with native aortic valve Serratia marcescens endocarditis with septic emboli presumed secondary to intravenous drug use. He was treated with vancomycin and cefepime then was transitioned to ceftriaxone and levofloxacin. The patient underwent aortic valve replacement on hospital day 3 and was transitioned to meropenem and levofloxacin for 6 weeks.
Discussion: The treatment strategies for both patients demonstrates that the optimal treatment strategy for Serratia marcescens endocarditis remains unclear. The gentamicin dosing for patient 1 demonstrates “synergy” and extended-interval dosing. Despite both dosing strategies being used, the patient continued to exhibit complications of the infection. Patient 2 demonstrates successful treatment of the infection with surgical intervention and a carbapenem/fluoroquinolone regimen.
Conclusion: These cases demonstrates that much remains unclear in the treatment of Serratia marcescens endocarditis and more studies and case reports are needed.
 
Publisher SCIENCEDOMAIN international
 
Date 2019-06-17
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
 
Identifier http://journalijmpcr.com/index.php/IJMPCR/article/view/30100
10.9734/ijmpcr/2019/v12i230100
 
Source International Journal of Medical and Pharmaceutical Case Reports; 2019 - Volume 12 [Issue 2]; 1-5
2394-109X
 
Language eng
 
Relation http://journalijmpcr.com/index.php/IJMPCR/article/view/30100/56474
http://journalijmpcr.com/index.php/IJMPCR/article/view/30100/56475
 
Rights Copyright (c) 2019 © 2019 Goodberlet et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library